Pharma bigwigs join hands for new TB drugJune 27th, 2012 - 8:58 pm ICT by IANS
New Delhi, June 27 (IANS) Pharmaceutical companies and research institutions in association with the Bill and Melinda Gates Foundation have stepped up efforts to aid research on a new drug for tuberculosis (TB), a disease that annually kills about three lakh in India.
“The partnership, TB Drug Accelerator (TBDA), will target the discovery of new TB drugs by collaborating on early-stage research. The long-term goal of the TBDA is to create a TB drug that cures patients in only one month,” a statement from pharma firm Sanofi said Wednesday.
Seven pharmaceutical companies and four research institutions have teamed up with the Bill and Melinda Gates Foundation for the goal.
Under the current TB course of medication, the patient has to be on antibiotics for at least six months, during which 20-30 percent patients drop out before completion.
With financial aid from the Gates Foundation, partners officially launched the TBDA in April and have begun the first round of screening for new TB drug candidates.
“TB drug discovery has reached a crossroads. Finding new and faster-acting TB drugs will take a new kind of partnership, connecting not only academia and industry, but drug company with drug company,” a Sanofi statement quoted Carl Nathan, professor and chairman of the department of microbiology and immunology at Weill Cornell Medical College, as saying.
The TBDA aims to develop five new preclinical drug candidates with treatment-shortening potential within 5 years and proof-of-concept for a one-month three-drug regimen within 10 years.
The participating pharmacy giants include Abbott, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Merck and Sanofi. The companies will share data with American research institutions like Infectious Disease Research Institute, National Institute of Allergy and Infectious Diseases and Weill Cornell Medical College.
“The TB Drug Accelerator establishes a new paradigm of cooperation in drug discovery. By working together on this, we can optimize our research and speed the development of one of the most pressing needs in global health,” said Chris Viehbacher, chief executive officer of Sanofi.
- Bill and Melinda Gates Foundation to focus on drugs, vaccine research - Mar 24, 2011
- Low-cost pain killer can wipe out resistant TB, say researchers - Sep 13, 2012
- Hyderabad foundation gets $100,000 grant for polio vaccine - May 10, 2012
- Electronic Nose can sniff tuberculosis - Nov 06, 2011
- GVK BIO to support global consortium - May 16, 2011
- New method detects aggressive prostate cancer - Aug 09, 2012
- A new 'Gate-way' for India's Africa diplomacy - May 31, 2012
- US firm gets $220 mn Gates grant to combat TB - Mar 15, 2012
- Central team to probe drug resistant TB cases in Mumbai - Jan 17, 2012
- Regulatory Conference Shows The Way Forward From Lessons Learnt In The Past - Aug 20, 2010
- Government to rope in chemists to fight TB (March 24 is World Tuberculosis Day) - Mar 24, 2012
- China reports 900,000 TB cases in 2011 - Mar 21, 2012
- Symposium shows progress in TB vaccines - Jun 08, 2010
- Zebrafish offers skin cancer clues - Apr 06, 2011
- Weight loss improves memory and concentration - Apr 13, 2011
Tags: bill and melinda gates, bill and melinda gates foundation, cornell medical college, drug discovery, drug regimen, eli lilly, foundation partners, infectious disease research, long term goal, melinda gates foundation, microbiology and immunology, national institute of allergy and infectious diseases, new paradigm, proof of concept, research institutions, stage research, tb drugs, tuberculosis tb, weill cornell medical, weill cornell medical college